MX369567B - ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT. - Google Patents

ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT.

Info

Publication number
MX369567B
MX369567B MX2018004348A MX2018004348A MX369567B MX 369567 B MX369567 B MX 369567B MX 2018004348 A MX2018004348 A MX 2018004348A MX 2018004348 A MX2018004348 A MX 2018004348A MX 369567 B MX369567 B MX 369567B
Authority
MX
Mexico
Prior art keywords
roryt
modulators
syndrome
disorder
disease
Prior art date
Application number
MX2018004348A
Other languages
English (en)
Inventor
Steven Goldberg
Gerald Kleymann
Olaf Kinzel
Gege Christian
Anne M Fourie
Hariharan Venkatesan
Steeneck Christoph
Hoffmann Thomas
Xiaohua Xue
Tanis Virginia
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54754732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX369567(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX369567B publication Critical patent/MX369567B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención comprende compuestos de la Fórmula I: (ver Fórmula) en donde:X, A1, A2, A3, A4, R1, R2 y R3se definen en la especificación; la invención comprende, además, un método para tratar o mejorar un síndrome, un trastorno o una enfermedad, en donde el síndrome, el trastorno o la enfermedad son artritis reumatoide o soriasis;Ia invención comprende, además, un método para modular la actividad de ROR?t en un mamífero por medio de la administración de una cantidad terapéuticamente eficaz de al menos un compuesto de acuerdo con la reivindicación 1.
MX2018004348A 2014-10-30 2015-10-30 ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT. MX369567B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462072563P 2014-10-30 2014-10-30
PCT/US2015/058193 WO2016069974A1 (en) 2014-10-30 2015-10-30 TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt

Publications (1)

Publication Number Publication Date
MX369567B true MX369567B (es) 2019-11-12

Family

ID=54754732

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018004348A MX369567B (es) 2014-10-30 2015-10-30 ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT.
MX2017005689A MX367912B (es) 2014-10-30 2015-10-30 ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017005689A MX367912B (es) 2014-10-30 2015-10-30 ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT.

Country Status (40)

Country Link
US (2) US9850236B2 (es)
EP (2) EP3212643B1 (es)
JP (3) JP6998204B2 (es)
KR (2) KR20170078750A (es)
CN (3) CN107827841A (es)
AR (2) AR102480A1 (es)
AU (2) AU2015339087B2 (es)
BR (2) BR122017023050A2 (es)
CA (1) CA2965512C (es)
CL (3) CL2017001042A1 (es)
CO (1) CO2017005014A2 (es)
CR (2) CR20170542A (es)
CY (1) CY1121716T1 (es)
DK (1) DK3212643T3 (es)
EA (2) EA035998B1 (es)
EC (1) ECSP17033054A (es)
ES (2) ES2858503T3 (es)
GT (1) GT201700090A (es)
HK (1) HK1258212A1 (es)
HR (1) HRP20190900T1 (es)
HU (1) HUE043624T2 (es)
IL (2) IL251865A0 (es)
JO (2) JOP20200117A1 (es)
LT (1) LT3212643T (es)
MA (1) MA40873B1 (es)
ME (1) ME03426B (es)
MX (2) MX369567B (es)
PE (2) PE20171649A1 (es)
PH (2) PH12017500800B1 (es)
PL (1) PL3212643T3 (es)
PT (1) PT3212643T (es)
RS (1) RS58613B1 (es)
SG (2) SG10201805355YA (es)
SI (1) SI3212643T1 (es)
SV (1) SV2017005429A (es)
TR (1) TR201907763T4 (es)
TW (2) TWI667230B (es)
UY (2) UY36377A (es)
WO (1) WO2016069974A1 (es)
ZA (3) ZA201703679B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201803869A (zh) * 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
US11230555B2 (en) 2018-03-12 2022-01-25 Escalier Biosciences B.V. Bicyclic RORγ modulators
MX2020009459A (es) 2018-03-12 2021-01-15 Escalier Biosciences B V Moduladores de ror-gamma espirocíclico.
US10975057B2 (en) 2018-06-18 2021-04-13 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of RORgT
CN112292373A (zh) 2018-06-18 2021-01-29 詹森药业有限公司 作为RORγt的调节剂的吡啶基吡唑类
CN112334450A (zh) * 2018-06-18 2021-02-05 詹森药业有限公司 作为RORγt的调节剂的苯基和吡啶基取代的咪唑
CA3103929A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl substituted pyrazoles as modulators of roryt
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91418A (en) 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
CA2195847A1 (en) 1994-07-27 1996-02-08 John J. Talley Substituted thiazoles for the treatment of inflammation
HUP0303829A3 (en) 2001-04-16 2006-02-28 Tanabe Seiyaku Co Large conductance calcium-acitvated k channel opener compounds, use thereof and pharmaceutical compositions containing them
ATE325608T1 (de) 2001-08-13 2006-06-15 Janssen Pharmaceutica Nv 2,4,5-trisubstituted thiazolyl derivative und deren antiinflammatorische wirkung
TWI336697B (en) * 2003-09-19 2011-02-01 Solvay Pharm Bv Thiazole derivatives as cannabinoid receptor modulators
US8188128B2 (en) 2005-05-12 2012-05-29 The University Of Medicine And Dentistry Of New Jersey Opioid receptor subtype-selective agents
GB0518237D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
EP1983980A4 (en) 2006-01-25 2010-05-05 Synta Pharmaceuticals Corp THIAZOL AND THIADIAZOL COMPOUNDS FOR USES IN RELATION TO INFLAMMATION AND IMMUNITY
WO2008064317A1 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
ES2426953T3 (es) 2008-07-17 2013-10-28 Bayer Cropscience Ag Compuestos heterocíclicos como pesticidas
WO2010118078A1 (en) * 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
EP2368886A1 (en) * 2010-03-01 2011-09-28 Phenex Pharmaceuticals AG Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease
HUE040420T2 (hu) 2010-03-11 2019-03-28 Univ New York Amidvegyületek, mint RORyT modulátorok és felhasználásuk
WO2011112264A1 (en) 2010-03-11 2011-09-15 New York University Compounds as rorϒt modulators and uses thereof
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
US9505798B2 (en) 2010-11-29 2016-11-29 New York University Steroid compounds as RORyt modulators and uses thereof
JP5981350B2 (ja) 2010-12-28 2016-08-31 ライオン株式会社 口腔状態の判定方法、並びにそのために用いられる分析用具、装置、及びプログラム
US9012651B2 (en) 2011-03-24 2015-04-21 Abbvie Inc. TRPV3 modulators
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
JP6054869B2 (ja) 2011-07-29 2016-12-27 武田薬品工業株式会社 複素環化合物
SG11201400456RA (en) 2011-09-09 2014-04-28 Univ New York Amido compounds as ror?tmodulators and uses thereof
GB201116641D0 (en) * 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
EP2800745B1 (en) 2011-12-02 2020-02-12 Phenex Pharmaceuticals AG Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
US20130190356A1 (en) 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
AR091194A1 (es) * 2012-05-31 2015-01-21 Phenex Pharmaceuticals Ag TIAZOLES SUSTITUIDOS POR CARBOXAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
CN105073729A (zh) * 2012-10-16 2015-11-18 詹森药业有限公司 RORγt的苯基连接的喹啉基调节剂
US9624210B2 (en) * 2012-12-12 2017-04-18 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
JP6368776B2 (ja) 2013-06-04 2018-08-01 アクチュラム・ライフ・サイエンス・アクチエボラーグ トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用
CN103333168B (zh) * 2013-07-23 2015-08-05 清华大学 一种酰胺类化合物及其制备方法与应用
US9663469B2 (en) 2013-09-09 2017-05-30 Bristol-Myers Squibb Company RORγ modulators
US20150072890A1 (en) 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer
US9725443B2 (en) 2013-09-20 2017-08-08 Bristol-Myers Squibb Company RORγ modulators
JP6320523B2 (ja) * 2013-10-15 2018-05-09 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγＴの第二級アルコールキノリニルモジュレータ
WO2015057629A1 (en) * 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv ALKYL LINKED QUINOLINYL MODULATORS OF RORyt
MX368721B (es) 2013-12-05 2019-10-14 Lead Pharma Holding Bv Moduladores de ror gamma (rory).
WO2015103510A1 (en) 2014-01-06 2015-07-09 Bristol-Myers Squibb Company Heterocyclic sulfone as ror-gamma modulators
TW201609634A (zh) 2014-01-06 2016-03-16 必治妥美雅史谷比公司 吡咯啶基碸類視色素相關孤兒受體γ（ＲＯＲγ）調節劑
EP3092215B1 (en) 2014-01-06 2018-10-17 Bristol-Myers Squibb Company Cyclohexyl sulfone ror gamma modulators
CN106132931B (zh) 2014-01-06 2019-08-02 百时美施贵宝公司 碳环砜RORγ调节剂
AU2015237788B2 (en) 2014-03-27 2021-03-11 Piramal Enterprises Limited ROR-gamma modulators and uses thereof
CN108064224B (zh) 2014-10-30 2022-03-29 詹森药业有限公司 作为Rorγt的调节剂的酰胺取代的噻唑
EP3212641B1 (en) 2014-10-30 2018-12-05 Janssen Pharmaceutica NV Thiazoles as modulators of roryt

Also Published As

Publication number Publication date
JP2018500287A (ja) 2018-01-11
EA201790942A1 (ru) 2017-09-29
MX367912B (es) 2019-09-11
US9850236B2 (en) 2017-12-26
ZA201805861B (en) 2019-11-27
PT3212643T (pt) 2019-06-17
HUE043624T2 (hu) 2019-08-28
JP6998204B2 (ja) 2022-02-04
PL3212643T3 (pl) 2019-08-30
ES2858503T3 (es) 2021-09-30
PH12017500800A1 (en) 2017-10-02
AU2019200228A1 (en) 2019-01-31
TW201927759A (zh) 2019-07-16
PH12017502105A1 (en) 2019-11-25
SI3212643T1 (sl) 2019-04-30
HK1258212A1 (zh) 2019-11-08
CN107108599A (zh) 2017-08-29
AU2015339087B2 (en) 2020-01-23
SV2017005429A (es) 2017-10-17
JOP20200117A1 (ar) 2017-06-16
DK3212643T3 (da) 2019-05-13
PE20180250A1 (es) 2018-02-02
CR20170166A (es) 2017-08-22
ES2724556T3 (es) 2019-09-12
IL255648B (en) 2020-06-30
IL251865A0 (en) 2017-06-29
AU2015339087A1 (en) 2017-05-11
AR102480A1 (es) 2017-03-01
ECSP17033054A (es) 2018-01-31
PE20171649A1 (es) 2017-11-13
TWI667230B (zh) 2019-08-01
EA201891562A3 (ru) 2019-04-30
EP3212643B1 (en) 2019-03-20
CL2019001514A1 (es) 2019-10-04
AU2019200228B2 (en) 2020-04-16
CY1121716T1 (el) 2020-07-31
EA035998B1 (ru) 2020-09-10
US10150762B2 (en) 2018-12-11
UY36377A (es) 2016-04-29
CO2017005014A2 (es) 2017-08-31
KR20170078750A (ko) 2017-07-07
PH12017500800B1 (en) 2017-10-02
KR20170127580A (ko) 2017-11-21
JP6623270B2 (ja) 2019-12-18
US20160122336A1 (en) 2016-05-05
ZA201703679B (en) 2019-06-26
JP2019059728A (ja) 2019-04-18
AR110155A2 (es) 2019-02-27
IL255648A (en) 2018-01-31
EA033699B1 (ru) 2019-11-18
EA201891562A2 (ru) 2018-12-28
CN107827841A (zh) 2018-03-23
TR201907763T4 (tr) 2019-06-21
SG10201805355YA (en) 2018-07-30
EP3354651B1 (en) 2021-01-06
MA40873B1 (fr) 2019-07-31
BR112017008816A2 (pt) 2017-12-19
MA40873A (fr) 2017-09-05
CL2017001042A1 (es) 2017-12-01
LT3212643T (lt) 2019-06-10
ZA201805860B (en) 2019-11-27
ME03426B (me) 2020-01-20
CA2965512A1 (en) 2016-05-06
RS58613B1 (sr) 2019-05-31
SG11201703323PA (en) 2017-05-30
GT201700090A (es) 2019-08-08
EP3354651A1 (en) 2018-08-01
CN112979630A (zh) 2021-06-18
CA2965512C (en) 2020-03-10
UY37517A (es) 2018-01-31
CR20170542A (es) 2018-02-20
CL2018000436A1 (es) 2018-07-06
JO3571B1 (ar) 2020-07-05
BR122017023050A2 (pt) 2019-09-10
TW201629027A (zh) 2016-08-16
TWI705057B (zh) 2020-09-21
US20170327492A1 (en) 2017-11-16
WO2016069974A1 (en) 2016-05-06
JP2020180129A (ja) 2020-11-05
EP3212643A1 (en) 2017-09-06
MX2017005689A (es) 2018-02-19
HRP20190900T1 (hr) 2019-07-12

Similar Documents

Publication Publication Date Title
PH12017500800A1 (en) TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt
MX358508B (es) Moduladores de quinolinilo unidos a metileno de receptor nuclear de acido retinoico-gamma-t.
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
MX2018013143A (es) 6-aminopiridin-3-il tiazoles como moduladores de ror?t.
PH12015500776A1 (en) Phenyl linked quinolinyl modulators of ror-gamma-t
MX2018003472A (es) Moduladores de la expresion de kras.
PH12016502062A1 (en) Compositions and methods for modulating completent factor b expression
BR112017008852A2 (pt) tiazóis substituídos com amida como moduladores do roryt
BR112016008258A2 (pt) moduladores de ror?t de quinolinila
WO2015057200A8 (en) Heteroaryl linked quinolinyl modulators of rorϒt
MX2020007369A (es) Moduladores de la expresion de dnm2.
BR112016008257A2 (pt) moduladores de roryt de álcool quinolínico secundário
BR112016008183A2 (pt) Moduladores de ror-gama-t de quinolinila ligados à fenila